# Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

> **NCT07305246** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First Hospital of China Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Letrozole
- **DRUG:** TAC/AC-T

## Key facts

- **NCT ID:** NCT07305246
- **Lead sponsor:** First Hospital of China Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07305246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07305246, "Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07305246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*